Composition for embolism

By combining embolizing microspheres with particle size of 30-150 microns and liquid embolizing agents with viscosity of 400-1000 mPa·s, a permanent sealing system is formed, which solves the problem that the embolizing microspheres and liquid embolizing agents in the prior art cannot achieve permanent sealing in the existing technology. The problem of this paper achieves efficient and long-lasting blocking of arterial blood vessels, reducing the risk of vascular reopening and thrombosis complications.

CN118903529APending Publication Date: 2024-11-08WEIMU MEDICAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410964942.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing embolization microspheres and liquid embolization agents are prone to complications such as reflux, mistuning, vascular reopening and thrombosis during the embolization process, and cannot achieve permanent blockage, especially in arterial vessels with fast blood flow. Blood vessels, causing ectopic embolism and blood leakage.

Method used

The combination of embolizing microspheres with particle size of 30-150 microns and liquid embolizing agent is adopted. The viscosity of liquid embolizing agent at 25°C is 400-1000mPa·s, and the curing time is 1-4min. It forms permanently through the specific viscosity and microsphere ratio. Blocking, the liquid embolizer solidifies at the target position to form a solid occlusion matrix, filling the gaps between the microspheres, reducing the probability of displacement and preventing blood flow from eroding.

Benefits of technology

It effectively reduces the displacement probability of the embolization site, realizes permanent blocking of arterial blood vessels, avoids vascular reblocking and thrombosis complications, ensures the durability and safety of embolization, and is especially suitable for tumor embolization of pulmonary artery or renal artery.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903529A_ABST
    Figure CN118903529A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biological medicines, in particular to the field of IPC A61L 24, and more particularly relates to a composition for embolism. The composition comprises embolism microspheres and a liquid embolism agent, the use method of the embolism composition comprises the following steps: S1, conveying the embolism microspheres and the conveying medium to a target position through a catheter; and S2, injecting a liquid embolism agent from the catheter, initiating polymerization by tissue fluid in the blood vessel, and quickly solidifying to form a completely closed system, thereby realizing permanent embolism. Comprehensive embolism of the blood vessel including the tail end can be achieved, the method is particularly suitable for embolism of the pulmonary artery or the renal artery, and permanent embolism can be achieved; and ectopic embolism and displacement risks caused by independent use of the embolism microspheres and the liquid embolism agent are avoided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomedicine technology, in particular to the field of IPC A61L 24, and more specifically to a composition for embolization. Background Art

[0002] Transcatheter arterial chemoembolization refers to the injection of an appropriate amount of embolic material into the target artery supplying the tumor through a microcatheter with the assistance of medical imaging equipment, so as to occlude the target artery and block the blood supply to the tumor tissue, leading to tumor ischemia, hypoxia, tumor cell necrosis and apoptosis. This therapy has rapidly developed into an important tumor treatment method in recent years. It has the advantages of minimally invasive, high selectivity and targeted controlled drug delivery in the treatment of vascular-rich malignant solid tumors. Embolic materials play an important role. Among them, the latest embolic microspheres have the advantages of regular shape, uniform particle size, good elasticity, and the ability to load tumor drugs, and have quickly become the preferred embolic material for this therapy. However, embolic microspheres have obvious insurmountable defects, including easy reflux during embolization, resulting in mis-embolism, and the microspheres in the target artery after embolization may also drift and "off-target" to other blood vessels, resulting in mis-embolism. In addition, the accumulation of microspheres at the embolization site cannot completely block the blood supply due to the presence of a large number of gaps, and there is still slight blood leakage to continue to supply the tumor tissue. There is a high probability that embolic microspheres and liquid embolic agents cannot permanently embolize, and may cause complications such as vascular recanalization and thrombosis.

[0003] CN114369354A discloses a liquid embolic agent for vascular embolism, which is formed by in-situ crosslinking of aldehyde-terminated star-shaped multi-arm polyethylene glycol with polyethyleneimine and polylysine crosslinking agents to form a hydrogel to achieve vascular embolism. However, since the liquid embolic agent needs to form a gel in situ, the gel reaction cannot occur instantaneously, but forms different degrees of distal embolism along the direction of blood flow according to the length of time required for the crosslinking reaction. However, for benign tumors and osteoarthritis embolism, distal embolism may cause insufficient blood supply to normal tissues and organs. Summary of the invention

[0004] The invention provides a composition for embolism, the components of which include embolism microspheres and liquid embolic agent.

[0005] The particle size of the embolic microspheres is 30-150 microns.

[0006] Preferably, the particle size of the embolic microspheres is 70-150 microns.

[0007] The embolic microspheres include at least one of polyvinyl alcohol, copolymer polyacrylate, and polyethylene glycol.

[0008] The copolymerized polyacrylates include at least one of polyvinyl acetate-copolymerized methyl acrylate, ethylene ferrocene-methyl methacrylate copolymer, ethylene-methyl acrylate-glycidyl methacrylate copolymer, and ethylene-methacrylic acid copolymer.

[0009] The polyvinyl alcohols include at least one of hydrolyzed polyvinyl alcohol, emulsified polyvinyl alcohol and carboxymethylated polyvinyl alcohol.

[0010] The number average molecular weight of the polyethylene glycol is 6000-12000.

[0011] The viscosity of the liquid embolic agent at 25° C. is 400-1000 mPa·s.

[0012] The solidification time of the liquid embolic agent in the blood vessel is 1-4 minutes.

[0013] There is a certain probability that embolic microspheres or liquid embolic agents (need to be used in conjunction with balloons) used alone cannot achieve permanent embolism, especially in arteries with faster blood flow rates, which may cause complications such as vascular recanalization and thrombosis. The gelatin sponge microspheres commonly used in existing technologies cannot penetrate into smaller blood vessels due to their fixed size, and can easily cause ectopic embolism. The present application has found that limiting the particle size of the embolic microspheres to 30-150 microns and the viscosity of the liquid embolic agent to 400-1000 mPa·s at 25° C. can effectively block arterial blood vessels, reduce the probability of displacement, and form permanent embolism. The liquid embolic agent in the embolic composition can solidify at the target site to form a solid occlusive matrix. The liquid embolic agent with a specific viscosity can fill the gaps between the microspheres and wrap the microspheres inside the liquid embolic agent. After solidification, a complete blocking system is formed to perform permanent embolism. Too high a viscosity can easily lead to reduced dispersibility with the microspheres, and too low a viscosity can easily be dispersed by the blood flow. At the same time, the solidification time of the liquid embolic agent in the blood vessel is limited to 1-4 minutes, while maintaining a high solidification speed, reducing the damage to the inner wall cells caused by the large amount of heat released during solidification.

[0014] Further research found that the liquid embolic agent is selected from Cordis Neurovascular, sold by the company The n-butyl cyanoacrylate (NBCA) of the brand can be used for embolization of the pulmonary artery or renal artery in the present application. In the prior art, NBCA is used for venous embolism, and it needs to be pressed for more than 3 minutes to solidify. Since the tumor site cannot be pressed, the present application selects a specific microsphere compound to slow down the blood flow rate and replace the pressing effect, so that it can be applied to the artery.

[0015] Preferably, the liquid embolic agent comprises at least one of the following substances: n-butyl cyanoacrylate, ethylene vinyl alcohol copolymer, poly(lactide-co-glycolide) copolymer, poly(hydroxyethyl methacrylate) and N-butyl-2-cyanoacrylate.

[0016] Preferably, the volume ratio of the embolic microspheres to the liquid embolic agent is 1:(0.3-20).

[0017] Further preferably, the volume ratio of the embolic microspheres to the liquid embolic agent is 1:(0.5-10).

[0018] More preferably, the volume ratio of the embolic microspheres to the liquid embolic agent is 1:(0.5-3).

[0019] More preferably, the liquid embolic agent contains n-butyl cyanoacrylate.

[0020] More preferably, the liquid embolic agent is selected from Cordis Neurovascular, sold by the company Brand of n-butyl cyanoacrylate (NBCA).

[0021] The embolic composition is used for embolization of pulmonary arteries or renal arteries.

[0022] The method for using the composition comprises the following steps:

[0023] S1, delivering embolic microspheres and delivery medium to the target site via a catheter;

[0024] S2, after the embolic microspheres are delivered, the liquid embolic agent is then injected through the catheter;

[0025] After the liquid embolic agent is injected through the catheter, it is polymerized by the tissue fluid in the blood vessel and solidifies rapidly to form a completely closed system, thereby achieving permanent embolism.

[0026] Preferably, the injection time of the liquid embolic agent is 2-3 minutes.

[0027] The delivery medium includes a contrast agent and a therapeutic agent.

[0028] The contrast agent may enable the physician to visualize the location and extent of the embolism by fluoroscopy, radioscopy, or other techniques.

[0029] The contrast agent may be any contrast agent commonly used in embolization.

[0030] Preferably, the contrast agent includes at least one of iohexol, ioversol and iodixanol.

[0031] The therapeutic agent may be at least one of a drug, a radioactive element, a compound suitable for embolization therapy to treat the affected organ.

[0032] Beneficial effects:

[0033] 1. The particle size of the embolic microspheres is limited to 30-150 microns, and the viscosity of the liquid embolic agent at 25°C is 400-1000 mPa·s, which can effectively block arterial blood vessels, reduce the probability of displacement, and form permanent embolism.

[0034] 2. The volume ratio of the embolic microspheres to the liquid embolic agent is 1:(0.3-20), and the injection time of the liquid embolic agent is 2-3 minutes. It can be used to avoid ectopic embolism, penetrate into permanent peripheral embolism, effectively prevent collateral circulation, and make the blood flow blockage in pulmonary artery or renal artery tumor embolism more complete, more lasting and effective.

[0035] 3. The present application uses the anterior capsule to block blood flow, which is simple to operate and has high blocking efficiency.

[0036] 4. The composite system of microspheres and liquid embolic agents of the present application can be loaded with contrast agents, so that the embolic position can be directly observed after surgery, avoiding the need for additional contrast agents and further simplifying the steps. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 This is the development of the embolization composition of Example 1 before embolization.

[0038] Figure 2 This is the development of the embolization composition of Example 1 in the embolization.

[0039] Figure 3 This is the development of the embolization composition of Example 1 after embolization.

[0040] Figure 4 This is an anatomical diagram of the patient 2 days after embolization with the composition of Example 1. DETAILED DESCRIPTION

[0041] Example 1

[0042] A composition for embolization, comprising embolic microspheres and liquid embolic agent.

[0043] The particle size of the embolic microspheres is 70-150 μm and is selected from polyvinyl alcohol (brand: ).

[0044] The liquid embolic agent is selected from Cordis Neurovascular, sold by the company Brand of n-butyl cyanoacrylate (NBCA).

[0045] A use of a composition for embolization, applied to embolization of a renal artery.

[0046] A method for using a composition for embolization comprises the following steps:

[0047] S1, 3 mL of embolic microspheres and delivery medium were delivered to the lower pole of the kidney using a 20 mL syringe;

[0048] S2, 1.5 mL of liquid embolic agent was injected into the lower pole of the kidney through the PTFE catheter.

[0049] The injection time of the liquid embolic agent is 1.5 min.

[0050] The delivery medium includes a contrast agent and a therapeutic agent.

[0051] The contrast agent is an ionic contrast agent and is not limited to a specific choice, such as iohexol, ioversol, iodixanol, etc.

[0052] Performance Testing Methods and Data

[0053] The use process of the embolic composition in Example 1 was observed by imaging ( Figure 1-3 ),like Figure 3 As shown, the lower pole of the kidney showed complete occlusion after embolization, and no ectopic embolism occurred.

[0054] Two days after embolization with the embolic composition of Example 1, the lower pole of the kidney was anatomically observed. Figure 4 As shown, the microspheres were found to be wrapped by glue (embolic agent) and completely solidified in the blood vessels, with excellent embolic effect.

Claims

1. A composition for embolization, characterized in that: Components include: Embolic microspheres and liquid embolic agents.

2. The composition for embolization according to claim 1, characterized in that: The particle size of the embolic microspheres is 30-150 microns.

3. The composition for embolization according to claim 2, characterized in that: The embolic microspheres include at least one of polyvinyl alcohol, copolymer polyacrylate, and polyethylene glycol.

4. The composition for embolization according to claim 3, characterized in that: The copolymerized polyacrylates include at least one of polyvinyl acetate-copolymerized methyl acrylate, ethylene ferrocene-methyl methacrylate copolymer, ethylene-methyl acrylate-glycidyl methacrylate copolymer, and ethylene-methacrylic acid copolymer.

5. The composition for embolization according to claim 3, characterized in that: The polyvinyl alcohols include at least one of hydrolyzed polyvinyl alcohol, emulsified polyvinyl alcohol and carboxymethylated polyvinyl alcohol.

6. The composition for embolization according to claim 3 or 5, characterized in that: The number average molecular weight of the polyethylene glycol is 6000-12000.

7. The composition for embolization according to claim 1, characterized in that: The viscosity of the liquid embolic agent at 25° C. is 400-1000 mPa·s.

8. The composition for embolization according to claim 7, characterized in that: The solidification time of the liquid embolic agent in the blood vessel is 1-4 minutes.

9. The composition for embolization according to claim 8, characterized in that: The volume ratio of the embolic microspheres to the liquid embolic agent is 1:(0.3-20).

10. The composition for embolization according to claim 9, characterized in that: The volume ratio of the embolic microspheres to the liquid embolic agent is 1:(0.5-10).